Beneficial Ownership Report · SCHEDULE 13G/A
Faeth Therapeutics, Inc.
FTHNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Faeth Therapeutics, Inc.
- Company CIK
- 0001829802
- Street
- 701 TILLERY STREET #12 #1010
- City
- AUSTIN
- State / country code
- TX
- Postal code
- 78702
Statement details
- Amendment number
- 1
- Security class
- Common Stock, $0.0001 par value per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Montanova Capital, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Group designation
- b
- Aggregate amount owned
- 2,310,703.00
- Percent of class
- 8.9
- Sole voting power
- 0.00
- Shared voting power
- 2,310,703.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,310,703.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Averill Master Fund, Ltd.
- Citizenship / organization
- E9
- Reporting person type
- CO
- Group designation
- b
- Aggregate amount owned
- 1,969,872.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 1,969,872.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,969,872.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Aaron Cowen
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Group designation
- b
- Aggregate amount owned
- 2,310,703.00
- Percent of class
- 8.9
- Sole voting power
- 0.00
- Shared voting power
- 2,310,703.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,310,703.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Faeth Therapeutics, Inc.
Principal executive office address
701 Tillery Street #12 #1010, Austin, Texas 78702
Item 2
Citizenship
Montanova Capital, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
Filing person
Montanova Capital, LLC Averill Master Fund, Ltd. Aaron Cowen
Principal business or residence address
Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America
Item 3
Not applicable indication
Y
Item 4
Percent of class
Montanova Capital, LLC - 8.9% Averill Master Fund, Ltd. - 7.6% Aaron Cowen - 8.9%
Amount beneficially owned
Montanova Capital, LLC - 2,310,703 Averill Master Fund, Ltd. - 1,969,872 Aaron Cowen - 2,310,703
Sole voting power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Shared voting power
Montanova Capital, LLC - 2,310,703 Averill Master Fund, Ltd. - 1,969,872 Aaron Cowen - 2,310,703
Sole dispositive power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Shared dispositive power
Montanova Capital, LLC - 2,310,703 Averill Master Fund, Ltd. - 1,969,872 Aaron Cowen - 2,310,703
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Montanova Capital, LLC. None of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the Common Stock, par value $0.0001 per share.
Item 7
Not applicable indication
N
Subsidiaries
Please see Exhibit B attached hereto.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification
Signature comments
* Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Signature 1
- Reporting person
- Montanova Capital, LLC
- Signed
- /s/ Andrew Nathanson
- Title
- Andrew Nathanson, General Counsel and Chief Compliance Officer
- Date
- 11/13/2026
Signature 2
- Reporting person
- Averill Master Fund, Ltd.
- Signed
- /s/ Andrew Nathanson
- Title
- Andrew Nathanson, Authorized Signatory
- Date
- 11/13/2026
Signature 3
- Reporting person
- Aaron Cowen
- Signed
- /s/ Aaron Cowen
- Title
- Aaron Cowen
- Date
- 11/13/2026
Filed exhibits
Company context
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph. D., together with scientific founders Lewis Cantley, Ph. D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph. D.; Scott Lowe, Ph. D.; and Greg Hannon, Ph. D. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.